Phase 1Data readout

Revuforj/Revumenib (SNDX-5613) + Gilteritinib (Menin Inhibitor)

Relapsed/Refractory Acute Myeloid Leukemia

SNDXSyndax Pharmaceuticals

Expected catalystDecember 31, 2026Company guidance: Dec 31, 2026

Catalyst overview

Event details

Drug or asset: Revuforj/Revumenib (SNDX-5613) + Gilteritinib (Menin Inhibitor)
Development stage: Phase 1
Event type: Data readout
Indication: Relapsed/Refractory Acute Myeloid Leukemia

Research summary

What is being tracked?

This catalyst tracks a Phase 1 data readout for Revuforj/Revumenib (SNDX-5613) + Gilteritinib (Menin Inhibitor) in Relapsed/Refractory Acute Myeloid Leukemia. The expected timing is based on the latest available company guidance and may change.

Development notes

04/30/26:- Phase 1 revumenib+gilteritinib R/R AML data expected in H2 2026. 08/04/26:- PR No update.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source

Revuforj/Revumenib (SNDX-5613) + Gilteritinib (Menin Inhibitor)

Event details

What is being tracked?

Development notes

Primary source

Related pipeline programs

Axatilimab (SNDX-6352) + Steroids

Axatilimab (SNDX-6352)

Axatilimab (SNDX-6352) + Jakafi® (ruxolitinib)

Revumenib (SNDX-5613) + venetoclax + decitabine and cedazuridine